Back to search results

Pilot Study of Emapalumab for CAR T-Cell Therapy-Associated Cytopenia

This study is looking at a drug called emapalumab to treat prolonged severe cytopenia (low blood cell counts) in people who have received CAR T-cell therapy for certain types of lymphoma. The main goal is to see how safe emapalumab is and if it causes any side effects. Researchers also want to see how well emapalumab works to improve blood cell counts. You may be able to join if you are at least 18 years old, have specific types of lymphoma (like FL, MCL, DLBCL, PMBCL, tFL, or HGBCL), and have already received standard CAR T-cell therapy (axi-cel, tisa-cel, or liso-cel). The study plans to enroll 32 participants, but its current status is unclear.

Study design
This is an interventional pilot study, meaning participants will receive a specific treatment. It aims to enroll 32 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and side effects will be monitored throughout the study, which is expected to last an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06285825

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

Recruiting
PHASE2Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~32 participants
Updated 2026-08-07 on ClinicalTrials.gov
What's tested:Emapalumab

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AEs)
Measured over Through study completion; an average of 1 year.

Conditions

Cytopenia

Explore related trials

B-Cell Non-Hodgkin LymphomaDiffuse Large B-Cell LymphomaFollicular LymphomaHigh Grade B-Cell LymphomaMantle Cell LymphomaPrimary Mediastinal Large B-Cell LymphomaTransformed Follicular Lymphoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Paolo Strati, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Paolo Strati, MD
[email protected]
(713) 745-1776
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Postmenopausal (no menses in greater than or equal to 12 consecutive months).
History of hysterectomy or bilateral salpingo-oophorectomy.
Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
History of bilateral tubal ligation or another surgical sterilization procedure.
Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of emapalumab administration.

What this trial measures

  • Safety and adverse events (AEs)Through study completion; an average of 1 year.

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0